Article
Retail investors crowd into Eli Lilly after weight-loss drug approval
Rating:
0.0
Views:
58
Likes:
1
Library:
1
Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock after the U.S. pharma major received a highly anticipated approval for its weight-loss drug Zepbound. Daily net purchases surged to $14.4 million on Nov. 8, when Zepbound was cleared in the U.S. and the U.K., hitting their highest levels since January 2021, as per data from Vanda Research.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value